Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-02T19:45:16.714Z.
Consensus retrieved: 2026-10-02T16:42:09.384Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-02T19:45:16.714Z.
Quote observation: 2026-10-02T19:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6690442df907739cb512a4e89a03dffaa5e4917a6ca2ab3506a10d5d4da185b9
Forward PE Ratio (N/A) = Dated Quote Price ($24.39) / Consensus Forward EPS ($-4.43)
FORWARD PE RATIO
N/A
Beam Therapeutics Inc.
Market Cap
$2.51B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.51B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.73B | 53.92 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 5.66 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $999.26M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $473.82M | 100.91 |
| NRC Health (NRC)vs › | $459.30M | 23.16 |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.30M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $24.39, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.43 | $-4.61 – $-4.22 | 11 | n/m |
| 2027-12-31 | $-4.79 | $-5.42 – $-3.90 | 9 | n/m |
| 2028-12-31 | $-4.59 | $-6.32 – $-3.39 | 10 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
